These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25372701)

  • 21. The need for developmental neurotoxicity studies in risk assessment for developmental toxicity.
    Hass U
    Reprod Toxicol; 2006 Aug; 22(2):148-56. PubMed ID: 16777374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune function tests for hazard identification: a paradigm shift in drug development.
    Gore ER
    Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):331-5. PubMed ID: 16623854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developmental Immunotoxicity (DIT) Testing: Current Recommendations and the Future of DIT Testing.
    vonderEmbse AN; DeWitt JC
    Methods Mol Biol; 2018; 1803():47-56. PubMed ID: 29882132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Developmental immunotoxicity (DIT): assays for evaluating effects of exogenous agents on development of the immune system.
    DeWitt JC; Peden-Adams MM; Keil DE; Dietert RR
    Curr Protoc Toxicol; 2012 Feb; Chapter 18():Unit 18.15. PubMed ID: 22511116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotoxicity: the risk is real.
    Selgrade MK
    Toxicol Sci; 2007 Dec; 100(2):328-32. PubMed ID: 17878151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developmental immunotoxicity of di-n-octyltin dichloride (DOTC) in an extended one-generation reproductive toxicity study.
    Tonk EC; de Groot DM; Penninks AH; Waalkens-Berendsen ID; Wolterbeek AP; Piersma AH; van Loveren H
    Toxicol Lett; 2011 Jul; 204(2-3):156-63. PubMed ID: 21557992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Critical aspects in reproductive and developmental toxicity testing of environmental chemicals.
    Buschmann J
    Reprod Toxicol; 2006 Aug; 22(2):157-63. PubMed ID: 16782303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. US FDA "Redbook II" immunotoxicity testing guidelines and research in immunotoxicity evaluations of food chemicals and new food proteins.
    Hinton DM
    Toxicol Pathol; 2000; 28(3):467-78. PubMed ID: 10862567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toxicity assessment strategies, data requirements, and risk assessment approaches to derive health based guidance values for non-relevant metabolites of plant protection products.
    Dekant W; Melching-Kollmuss S; Kalberlah F
    Regul Toxicol Pharmacol; 2010 Mar; 56(2):135-42. PubMed ID: 19883711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The mouse as a model for developmental immunotoxicology.
    Holladay SD; Blaylock BL
    Hum Exp Toxicol; 2002; 21(9-10):525-31. PubMed ID: 12458911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of developmental immunotoxicity and immune dysfunction in chronic disease and cancer.
    Dietert RR
    Reprod Toxicol; 2011 Apr; 31(3):319-26. PubMed ID: 20854896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The accuracy of extended histopathology to detect immunotoxic chemicals.
    Germolec DR; Kashon M; Nyska A; Kuper CF; Portier C; Kommineni C; Johnson KA; Luster MI
    Toxicol Sci; 2004 Dec; 82(2):504-14. PubMed ID: 15342959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemical testing strategies for predicting health hazards to children.
    Lamb JC; Brown SM
    Reprod Toxicol; 2000; 14(2):83-94. PubMed ID: 10825671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relative sensitivity of developmental and immune parameters in juvenile versus adult male rats after exposure to di(2-ethylhexyl) phthalate.
    Tonk EC; Verhoef A; Gremmer ER; van Loveren H; Piersma AH
    Toxicol Appl Pharmacol; 2012 Apr; 260(1):48-57. PubMed ID: 22310177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, state of the science, knowledge gaps, and recommendations.
    Collinge M; Burns-Naas LA; Chellman GJ; Kawabata TT; Komocsar WJ; Piccotti JR; Shenton J; Wierda D
    J Immunotoxicol; 2012; 9(2):210-30. PubMed ID: 22428536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of health risks resulting from early-life exposures: Are current chemical toxicity testing protocols and risk assessment methods adequate?
    Felter SP; Daston GP; Euling SY; Piersma AH; Tassinari MS
    Crit Rev Toxicol; 2015 Mar; 45(3):219-44. PubMed ID: 25687245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of immunotoxic effects of chemicals and assessment of their relevance to man.
    Trizio D; Basketter DA; Botham PA; Graepel PH; Lambré C; Magda SJ; Pal TM; Riley AJ; Ronneberger H; Van Sittert NJ
    Food Chem Toxicol; 1988 Jun; 26(6):527-39. PubMed ID: 3049276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility of human trials to assess developmental immunotoxicity, and some comparison with data on New World monkeys.
    Neubert RT; Webb JR; Neubert D
    Hum Exp Toxicol; 2002; 21(9-10):543-67. PubMed ID: 12458914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early-life immune insult and developmental immunotoxicity (DIT)-associated diseases: potential of herbal- and fungal-derived medicinals.
    Dietert RR; Dietert JM
    Curr Med Chem; 2007; 14(10):1075-85. PubMed ID: 17456021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.